Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Chronic Lymphocytic Leukemia with In Vitro Sensitivity
NCT01441882Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2011
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic lymphocytic leukemia (CLL), sponsored by OHSU Knight Cancer Institute. Started Oct 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01441882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441882.